Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Esperion Therapeutics Inc (NASDAQ:ESPR)

38.94
Delayed Data
As of Mar 24
 -1.46 / -3.61%
Today’s Change
9.40
Today|||52-Week Range
48.21
+211.02%
Year-to-Date
Benzinga's Option Alert Recap From March 21
Mar 21 / Benzinga - Paid Partner Content
Biotechs Remain the Best Place For Stock Picking
Mar 20 / TheStreet.com - Paid Partner Content
Company News for March 21, 2017
Mar 21 / Zacks.com - Paid Partner Content
Trump, Biogen and Amgen Hammer Healthcare ETFs
Mar 20 / Zacks.com - Paid Partner Content
Biotech Premarket Movers: Esperion, Minerva and BioCryst
Mar 21 / TheStreet.com - Paid Partner Content
Biotech Premarket Movers:
Mar 20 / TheStreet.com - Paid Partner Content
How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More
Mar 20 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close40.40
Today’s open40.56
Day’s range38.65 - 40.75
Volume1,606,225
Average volume (3 months)1,368,373
Market cap$911.3M
Dividend yield--
Data as of 3:59pm ET, 03/24/2017

Growth & Valuation

Earnings growth (last year)-47.35%
Earnings growth (this year)--
Earnings growth (next 5 years)-5.76%
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book3.99

Competitors

 Today’s
change
Today’s
% change
DEPODepomed Inc+0.05+0.34%
INSMInsmed Inc+0.16+1.02%
FLXNFlexion Therapeutics...+1.02+3.89%
SGYPSynergy Pharmaceutic...+0.10+2.24%
Data as of 3:59pm ET, 03/24/2017

Financials

Next reporting dateMay 15, 2017
EPS forecast (this quarter)-$1.43
Annual revenue (last year)$0.00
Annual profit (last year)-$75.0M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Tim M. Mayleben
COO, Executive VP-Research &
Development
Narendra D. Lalwani
Corporate headquarters
Ann Arbor, Michigan

Forecasts


Search for Jobs